Platform Construction and Clinical Application of 5G Technology for Remote Operation of the R-One™ Robot in Percutaneous Coronary Intervention
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 60
- 试验地点
- 9
- 主要终点
- Clinical success rate of the surgery
研究概览
简要总结
Patients with coronary artery disease requiring PCI treatment were enrolled in the study.
All patients underwent PCI with the robotic R-OneTM System (R-One Vascular Robotics, Cathbot). The system was designed for coronary PCI and consists of 2 major components: the command unit and a bedside robot. The command unit is a radiation-shielded, mobile workstation that was positioned in the corner of the catheterization laboratory. The interventional cardiologist sits at the command unit and remotely performs the PCI using the console joysticks. Commands from the control console are delivered as electrical signals along a communication cable that runs from the control console to the robotic drive, on which a sterile cassette is placed. The cassette, which is loaded with the robot and connected to the guiding catheters, imposes axial and rotational forces on the intracoronary devices. Fluoro-scopic, electrocardiographic, and hemodynamic images are "slaved" to the duplicate monitors inside the cockpit, enabling visualization from a closer distance.
After completion of diagnostic angiography, the guiding catheter was positioned at the ostium of the coronary artery and connected to the disposable cassette on the robotic drive. The guidewire was loaded into the cassette before starting the robotic-enhanced PCI. The treatment plan is decided by the doctor according to the patients' situation. All intracoronary devices were to be manipulated exclusively by the robotic system, with bailout to manual conversion when needed.
The primary endpoints were clinical procedural success and device technical success. The necessary sample size for testing the endpoint of clinical and technical procedural success was calculated on the basis of the target value. The statistical analysis results show that the lower limit of the 95% confidence interval of the clinical success rate and the technical success rate of the operation is greater than 90% of the target value, and the invalid hypothesis is rejected. Both primary endpoints had to be met for the study to be declared successful. Data were analyzed on an intention-to-treat basis. Standard summary statistics were calculated for all patient and study outcome variables. Continuous variables were summarized using estimated means, standard deviations, minimums, maximums, medians, and interquartile ranges. Categorical data were summarized using frequencies, percentages, and 95% confidence interval.
详细描述
- Purpose To evaluate the effectiveness and safety of 5G-enabled remote control of the R-OneTM vascular interventional navigation control system for percutaneous coronary interventions.
- Research design A prospective, multicenter, exploratory clinical trial. Subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled into the clinical study, and the subjects are randomly grouped by using the interactive web response system (IWRS) applet (MedLand Centralized Randomization Management System). The surgeons completed the robotic-assisted surgical operation using the investigational device during cardiovascular PCI treatment. The investigator is also required to evaluate the performance of the investigational device during the procedure and ultimately determine the safety and efficacy of its clinical application.
- Device The investigational device was R-One Vascular Interventional Navigation Control System developed and produced by Robocath, and was composed of a platform (instruction unit, robot, support joint arm), a consumable set (cartridge, instruction unit protective sleeve), and a remote workstation.
- Scope of Trial The subjects scope of the clinical trial: Patients requiring cardiovascular PCI.
- Experimental Procedure Information of all the patients who have signed the Informed Consent Form and actually pass the screening will be registered in the screening/enrollment log sheet. If a subject is excluded from the trial, the investigator should specify the reasons for screening failure. If a subject is enrolled in the trial but does not use the investigational device, the reason should also be recorded.
All subjects enrolled in the trial will be given a corresponding enrollment number.
72-hour pre-operative collected ECG, cardiac enzyme, and concomitant medication records.
Operation day visit The investigator is also required to complete the cardiology robot-assisted surgical treatment using the investigational device and record the procedure, LED Scale, SME Scale, and device Performance Evaluation Pre-discharge visit The investigator shall collect the blood test, creatinine, ECG. cardiac enzyme, concomitant medication records.
1 month post-operative visit The investigator shall collect the concomitant medication records.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age ≤ age ≤ 80 years of age.
- •Have clinical indication(s) for PCI and need to be treated with a PCI procedure.
- •Subjects voluntarily signed an informed consent form and were willing to complete follow-up visits.
- •Visual description of target lesion diameter stenosis ≥70% (or ≥50% accompanied with clinical evidence of myocardial ischemia within that range;
- •2.5 mm ≤reference vessel diameter by visual description ≤ 4.0 mm.
- •Target lesion length ≤34.0 mm by visual description (If it is made up of multiple small lesions, the distance of which should not exceed 10 mm) and can be fully covered by a single stent. There are no less than 2.0 mm normal segmental vessels at the proximal and distal margins of the diseased region.
- •≤2 target vessels to be treated, one single stent for each target lesion per target vessel, and target lesions can not be treated through stages.
排除标准
- •Subjects have undergone other PCI within 72 hours prior to the R-One PCI procedure;
- •Subjects have undergone PCI within 30 days prior to the R-One PCI procedure and have experienced a MACE or other serious adverse event;
- •Acute myocardial infarction (MI) within one week prior to scheduled R-One PCI procedure;
- •Severe heart failure (NYHA ≥ Class III);
- •Cardiogenic shock within 48 hours prior to the PCI procedure;
- •Pregnant and lactating women, or women with plans to become pregnant during the clinical trial;
- •Subjects with allergies to aspirin, heparin, clopidogrel, contrast media, metallic materials and rapamycin;
- •Subjects with a platelet count <100 x 109/L or >700 x 109/L and a white blood cell (WBC) count <3 x 109/L (e.g., thrombocytopenia, thrombocytosis, neutropenia or leukopenia);
- •Subjects with creatinine levels ≥ 177 umol/L;
- •Subjects had a stroke within 30 days prior to the planned R-One PCI procedure.
- •Subjects with an active peptic ulcer or upper gastrointestinal hemorrhage within 6 months prior to the PCI procedure.
- •Subjects with a history of massive haemorrhage or coagulation disorder, or refusal of blood transfusion within the previous 6 months.
- •Subjects are currently enrolled in another clinical study that has not yet completed the entire follow-up period.
- •The investigators determined that the patient was not applicable for robot-assisted PCI.
- •TIMI blood flow grade of <3 for the target lesion.
- •In-stent restenosis, or the target vessel has implanted a stent previous which in close proximity to the target lesion.
- •Need other treatments (e.g., atherectomy or laser treatment) in addition to balloon angioplasty and stentoplasty.
- •Coronary anatomy deemed unsuitable for robot-assisted PCI as determined by the operator.
结局指标
主要结局
Clinical success rate of the surgery
时间窗: Operation day
Calculation formula: Clinical success rate = number of subjects that were clinical successes ÷ number of subjects that received surgical treatment × 100%. Evaluation method: The target lesion was treated with test device, and the residual stenosis in the target vessel (visual description by angiography) reduced to less than 30% after PCI and a TIMI grade of 3. No major adverse cardiovascular events (MACE) occurred in the hospital.
Success rate of surgical techniques
时间窗: Operation day
Calculation formula: Technical success rate = number of subjects that were technical successes ÷ number of subjects received surgical treatment × 100% Evaluation method: The Robot-assisted PCI procedure was successfully completed without any unplanned manual assistance or shift to manual operation. Definition of planned manual assistance: During robotic surgery: Reposition of guidewires or stents/balloons, manual translation/rotation of guidewires or stents/balloons to guiding catheters, reposition of guiding catheters and usage of any device that is not compatible with the robotic platform Definition of unplanned manual assistance: Manual translation/rotation of the guidewire and/or manual translation of the stent/balloon once the guidewire has left the guiding catheter Definition of the shift to manual operation: Any situation during the PCI procedure that results in the shift to manual operation. System restart failure during robotic surgery
次要结局
- Procedure duration(Operation day)
- Radiation exposure to the patient(Operation day)
- Duration of robot-assisted treatment(Operation day)
- Radiation exposure to surgeons(Operation day)
- Contrast dose(Operation day)
- MACE(Operation day and 1 month post-operative)